@article{oai:u-ryukyu.repo.nii.ac.jp:02011226,
 author = {Morichika, Kazuho and Tomoyose, Takeaki and Hanashiro, Taeko and Shimabukuro, Natsuki and Tamaki, Keita and Tedokon, Iori and Nishi, Yukiko and Nakachi, Sawako and Karube, Ken-nosuke and Fukushima, Takuya and Katoh, Takeharu and Ohshima, Koichi and Masuzaki, Hiroaki},
 issue = {10},
 journal = {Internal Medicine},
 month = {},
 note = {Adult T cell leukemia / lymphoma (ATL) is one of the most aggressive hematological malignancies caused by human T-lymphotropic virus type-I (HTLV-1). Mogamulizumab is a new defucosylated humanized monoclonal antibody agent which targets C-C chemokine receptor type 4 (CCR4) expressed occasionally on the surface of ATL cells. However, adverse events such as drug eruptions have also been highlighted, at least in part, via the dysfunction of regulatory T cells (Tregs). We herein report a pronounced recurrence of systemic psoriasis vulgaris accompanied by the treatment of mogamulizumab in a patient with ATL. Pathological examinations may suggest a mechanistic link between the recurrence of autoinflammatory diseases and anti-CCR4 antibody therapies., 論文},
 pages = {1345--1349},
 title = {Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma : Insight into Autoinflammatory Diseases},
 volume = {55},
 year = {2016}
}